Mechanism · Research Data · Protocols · Compound Information
Semax is a synthetic heptapeptide, an analogue of the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10) with an additional Pro-Gly-Pro sequence. It belongs to a class of compounds investigated for their potential influence on cognitive functions and neuroprotection. Unlike ACTH, Semax lacks hormonal activity but retains and often has been observed to support the neuroregulatory properties associated with the parent molecule.
Research into Semax primarily explores its potential applications in areas related to neural plasticity, attention, memory, and resilience to stress. Its unique structure is thought to confer enhanced stability and targeted action within the central nervous system. This guide is for educational and research purposes only. Not medical advice.
| Evidence Type | Status |
|---|---|
| Human RCT | ✔ (primarily in specific regions, e.g., Russia) |
| Observational | ✔ (clinical use in specific regions) |
| Animal Studies | ✔ |
| In Vitro | ✔ |
| Regulatory Approval | ✗ (not approved for human therapeutic use by HPRA/HSA or major Western regulatory bodies) |
Semax is primarily understood to exert its effects through interactions within the brain's neuroregulatory systems. It is thought to modulate the activity of the melanocortin system, specifically interacting with melanocortin receptors (MC1, MC3, MC4, MC5), though its precise binding profile and downstream effects are areas of ongoing investigation. This interaction is hypothesised to influence various physiological processes, including neurogenesis, synaptic plasticity, and inflammatory responses within the central nervous system.
Further research suggests that Semax may influence the levels and activity of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), which are crucial for neuronal survival, growth, and differentiation. Additionally, experimental models have indicated its potential to modulate the metabolism of monoamine neurotransmitters like dopamine, serotonin, and norepinephrine, which play key roles in mood, attention, and cognitive processes. This multifaceted interaction across several neurotransmitter and neurotrophic systems contributes to the broad spectrum of effects observed in research.
Research has investigated Semax for its potential to has been observed to support cognitive functions, particularly in areas of attention, memory, and learning. Animal models and some human studies (e.g., in Russia) have observed improvements in sustained attention, information processing speed, and the consolidation of memory. It has been investigated for its use in subjects experiencing cognitive fatigue or following conditions that impair cognitive performance.
Semax has been studied extensively for its neuroprotective properties, primarily in animal models of neurological injury. Research suggests it may offer protection against various forms of brain damage, including ischemic stroke, traumatic brain injury, and oxidative stress. Studies have observed a reduction in neuronal damage and improved functional recovery in these experimental models, potentially through mechanisms involving antioxidant activity and the modulation of inflammatory pathways.
Experimental models have investigated Semax's potential effects on mood and stress responses. Research in rodents has observed anxiolytic-like effects and a reduction in despair behaviours associated with depression-like states. These effects are thought to be mediated by its influence on monoamine neurotransmitter systems and the hypothalamic-pituitary-adrenal (HPA) axis, contributing to enhanced resilience against various stressors.
Beyond its direct neurological effects, Semax has been investigated for its role in modulating the immune system. In vitro and animal studies have suggested it can influence both innate and adaptive immune responses, potentially impacting inflammation and the body's general resistance. This area of research explores the intricate link between the nervous and immune systems, often referred to as neuroimmunomodulation.
| Study / Model | Reported Effect |
|---|---|
| Rat model of transient cerebral ischemia | Significantly reduced neurological deficits and infarct volume. |
| Human study (healthy volunteers) | Observed improvements in selective attention and memory recall. |
| In vitro (primary neuronal cultures) | Increased expression of BDNF and NGF mRNA, suggesting neurotrophic support. |
| Animal model of chronic unpredictable stress | Reduced anxiety-like behaviour and normalized levels of stress hormones. |
| Human study (post-stroke recovery, specific region) | Faster recovery of cognitive functions and motor skills. |
| Mouse model of traumatic brain injury | Decreased neuronal apoptosis and attenuated inflammation. |
| Human study (glaucoma patients, specific region) | Reported improvements in visual field parameters and optic nerve function. |
Experimental research protocols only — not dosing recommendations.
| Protocol | Dose | Duration | Frequency | Research Context |
|---|---|---|---|---|
| Low Range | ~300-600 mcg intranasally | 5-10 days | Once daily | Initial exploration of cognitive effects in animal models. |
| Standard Range | ~600-1200 mcg intranasally | 10-14 days | 1-2 times daily | Typical range for studies on neuroprotection and cognitive enhancement. |
| Advanced Range | ~1200-2400 mcg intranasally | 7-21 days | 2-3 times daily | Investigated in more acute or intensive neurorestorative research. |
No severe adverse events have been widely reported in available published literature concerning Semax research at standard experimental doses.
Peptide dosing calculator, cycle planner, macro guide and more. No signup required.
Explore Free Tools